Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Summary of Results: Adding Biologic DMARDs to JIA Treatment (Methotrexate Permitted)
Disease activity improved when biologic DMARDs were added to treatment, but the statistical significance of these effects is not established. Health status improved when biologic DMARDs were added to treatment.
Improvements in a measure of inflammation, ESR, were inconsistent across studies. Radiographic evidence of progression was not reported.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | anti-inflammatory | methotrexate | disease activity | health status | erythrocyte sedimentation rate | ESR
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.